Search results for "medicine.vaccine"

showing 10 items of 33 documents

Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in …

2017

The ESCULAPIO Project aims at increasing awareness on vaccine preventable infectious diseases (VPID) and vaccinations in different target populations and to spread the culture of prevention. Information/training interventions on VPID have been developed and health promotion activities for the general population, students and their parents, teachers and health care workers (HCWs) were set up. In Tuscany, educational courses on VPID in high schools were organized and students were stimulated to prepare informative materials on VPID for lower grade school pupils. In Liguria, an educational card game (named 'Vaccine at the Fair') was presented to children of primary schools. Stands in shopping …

MalePediatricsVaccination schedulePsychological interventionSettore MED/42 - Igiene Generale E Applicataawareness; communication; general population; health care workers; infectious diseases; students; vaccination coverage; vaccineinfectious diseasesgeneral population0302 clinical medicinevaccineHealth careImmunology and Allergyawareness030212 general & internal medicineeducation.field_of_studyVaccinesvaccination coverageSchoolsstudentscommunicationVaccinationResearch PapersVaccinationItalyOrder (business)Femalemedicine.medical_specialtystudentAdolescentinfectious disease030231 tropical medicineImmunologyPopulationeducationawarenehealth care workers03 medical and health sciencesYoung AdultmedicineDisease Transmission InfectiousHumanseducationHealth communicationPharmacologybusiness.industryHealth promotionHealth Communicationhealth care workerFamily medicinebusinessHuman vaccinesimmunotherapeutics
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.

2014

Abstract Background In July 2006, Priorix-Tetra™, a combined measles-mumps-rubella-varicella (MMRV) vaccine, was licensed in Germany. Since a postlicensure study had shown a more than twofold elevated risk of febrile convulsions (FC) after first dose vaccination with the combined MMRV vaccine ProQuad ® compared to separately administered MMR and V vaccines (MMR+V), the Paul-Ehrlich-Institute, the German regulatory agency for vaccine licensing and safety, requested a study investigating the risk of FC for Priorix-Tetra™. Methods We performed a matched cohort study based on claims data of more than 17 million insurees in the German Pharmacoepidemiological Research Database. All children born …

MalePediatricsmedicine.medical_specialtymedicine.vaccineSeizures FebrileChickenpox VaccineCohort StudiesGermanymedicineClinical endpointHumansVaccines CombinedFebrile convulsionsMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryConfoundingVaccinationPublic Health Environmental and Occupational HealthInfantOdds ratioVaccinationInfectious DiseasesImmunizationRelative riskChild PreschoolMolecular MedicineFemalebusinessMeasles-Mumps-Rubella VaccineVaccine
researchProduct

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeableH…

2016

ABSTRACT Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib…

Malemedicine.medical_specialtyAntipyreticsparacetamolImmunologyIbuprofenBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causeGastroenterologyHaemophilus influenzaePneumococcal Vaccines03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineAntipyretic10-valent pneumococcal conjugateAcetaminophenfeverPharmacologyReactogenicityRomaniabusiness.industryIncidenceorganic chemicalsImmunogenicityInfantIbuprofenResearch PapersAntibodies BacterialHealthy VolunteersAcetaminophenVaccinationTreatment OutcomeImmunologyFemaleprophylaxisbusinessmedicine.drugHuman Vaccines & Immunotherapeutics
researchProduct

COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis

2021

The current challenge worldwide is the administration of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Even if rarely, severe vascular adverse reactions temporally related to vaccine administration have induced diffidence in the population at large. In particular, researchers worldwide are focusing on the so-called “thrombosis and thrombocytopenia after COVID-19 vaccination”. This study aims to establish a practical workflow to define the relationship between adverse events following immunization (AEFI) and COVID-19 vaccination, following the basic framework of the World Health Organization (WHO). Post-mortem investigation plays a pivotal role to support this c…

Medicine (General)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryPopulation030204 cardiovascular system & hematologyArticledeep vein thrombosisAutoimmune thrombocytopenia03 medical and health sciencesautopsyR5-9200302 clinical medicinevaccinestandard protocolMedicineIntensive care medicineeducationAdverse effectdisseminated intravascular coagulationeducation.field_of_studySARS-CoV-2business.industryCOVID-19post-mortem investigationCausalityVaccinationimmune thrombocytopeniaImmunization030220 oncology & carcinogenesisvaccination campaignbusinessDiagnostics
researchProduct

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.

2006

Combination vaccines against common childhood diseases are widely used, provide an improved coverage, are more convenient and are more cost-effective than multiple injections. We conducted a study to evaluate the safety and immunogenicity of a combined measles-mumps-rubella-varicella (MMRV) candidate vaccine in comparison with the separate administration of licensed measles-mumps-rubella (MMR; Priorix) and varicella (V; Varilrix) vaccines.Healthy children 12-18 months of age received 2 doses of MMRV vaccine (3 lots) 6-8 weeks apart (MMRV group) or 1 dose of MMR vaccine administered concomitantly with 1 dose of varicella vaccine, followed by a second dose of MMR at 6-8 weeks later (MMR+V gro…

Microbiology (medical)MaleHerpesvirus 3 HumanFeverPainHyperemiamedicine.vaccineAntibodies ViralRubellaMeaslesCombination vaccinesChickenpox VaccinemedicineHumansVaccines CombinedMeasles mumps rubella varicellaMMRV vaccinebusiness.industryImmunogenicityvirus diseasesInfantmedicine.diseaseInfectious DiseasesMumps virusMeasles virusImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFemaleViral diseasebusinessMeasles-Mumps-Rubella VaccineThe Pediatric infectious disease journal
researchProduct

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…

2017

ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…

OncologyAdultmedicine.medical_specialtyReferralGenotypeImmunologyUterine Cervical NeoplasmsHPV vaccinesCervix UteriHospital based study03 medical and health sciences0302 clinical medicineHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicinevaccineGenotypemedicinePrevalenceHumansImmunology and Allergy030212 general & internal medicinePapillomavirus VaccinesquadrivalentReferral and ConsultationSicilyFemale populationsquamous intraepithelial lesionGynecologyPharmacologyPotential impactHpv typesbusiness.industryPapillomavirus InfectionsHPV infectionsquamous intraepithelial lesionsvirus diseasesmedicine.diseaseUterine Cervical DysplasiaResearch Papersimpact estimateHPV infection; impact estimate; nonavalent; quadrivalent; squamous intraepithelial lesions; vaccine; Immunology and Allergy; Immunology; Pharmacology030220 oncology & carcinogenesisHPV infectionFemalebusinessnonavalent
researchProduct

Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-anal…

2016

ABSTRACT Low measles, mumps and rubella (MMR) immunization levels in European children highlight the importance of identifying determinants of parental vaccine uptake to implement policies for increasing vaccine compliance. The aim of this paper is to identify the main factors associated with partial and full MMR vaccination uptake in European parents, and combine the different studies to obtain overall quantitative measures. This activity is included within the ESCULAPIO project, funded by the Italian Ministry of Health. ORs and CIs were extracted, sources of heterogeneity explored and publication bias assessed. Forty-five papers were retrieved for the qualitative study, 26 of which were i…

ParentsHealth Knowledge Attitudes PracticePediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinedeterminant; measles; mumps and rubella; parents; uptake; vaccine; Immunology and Allergy; Immunology; PharmacologyImmunologyReviewdeterminantSettore MED/42 - Igiene Generale E ApplicataMMR vaccineRubellaMeasles03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsHumansmeaslesmeasleImmunology and AllergyMedicinemumps and rubella030212 general & internal medicineMumpsRubellaPharmacologyPracticebusiness.industryHealth KnowledgeVaccinationPublication biasPatient Acceptance of Health Caremedicine.diseaseEuropeVaccinationparentdeterminant; measles; mumps and rubella; parents; uptake; vaccine; Europe; Health Knowledge Attitudes Practice; Humans; Measles; Measles-Mumps-Rubella Vaccine; Mumps; Patient Acceptance of Health Care; Rubella; Vaccination; ParentsAttitudesuptakeMeta-analysisMarital statusbusinessMeasles-Mumps-Rubella VaccineDemographyHuman Vaccines & Immunotherapeutics
researchProduct

A combination vaccine against measles, mumps, rubella and varicella.

2008

A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after the first and second dose are similar to those observed after concomitant administration of the MMR and varicella vaccines. Furthermore, the clinical profile of this combination vaccine, in terms of injection- site and general tolerability, is similar to that of the component vacci…

Pediatricsmedicine.medical_specialtymedicine.vaccineMeaslesRubellaChickenpox VaccineChickenpoxmedicineHumansPharmacology (medical)Vaccines CombinedSeroconversionChildMumpsImmunization ScheduleRubellaPharmacologyAttenuated vaccineMMRV vaccinebusiness.industryVaccinationAntibody titerInfantGeneral Medicinemedicine.diseaseVirologyVaccinationTolerabilityChild PreschoolbusinessMeasles-Mumps-Rubella VaccineMeaslesDrugs of today (Barcelona, Spain : 1998)
researchProduct

Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials.

2019

According to WHO (World Health Organization) reports, more than 770,000 people died from HIV and almost 1.7 million people becoming newly infected in the worldwide in 2018. Therefore, many attempts should be done to produce a forceful vaccine to control the AIDS. DNA-based vaccines have been investigated for HIV vaccination by researches during the recent 20 years. The DNA vaccines are novel approach for induction of both type of immune responses (cellular and humoral) in the host cells and have many advantages including high stability, fast and easy of fabrication and absence of severe side effects when compared with other vaccination methods. Recent studies have been focused on vaccine de…

Pharmaceutical ScienceHIV Infections02 engineering and technologyVirusDNA vaccination03 medical and health sciencesImmune systemAcquired immunodeficiency syndrome (AIDS)AntigenAdjuvants ImmunologicmedicineVaccines DNAAnimalsHumansVector (molecular biology)030304 developmental biologyAIDS Vaccines0303 health sciencesClinical Trials as TopicImmunity Cellularbusiness.industryVaccination021001 nanoscience & nanotechnologymedicine.diseaseImmunity HumoralVaccinationClinical trialImmunology0210 nano-technologybusinessJournal of controlled release : official journal of the Controlled Release Society
researchProduct